Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 0.70 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.70 |
| ▸ | AHCY | P23526 | 8/20 | 0.63 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.61 |
| ▸ | PI4KA | P42356 | 1/20 | 0.60 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.60 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.60 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.60 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10009500 | 0.93 | ADORA2A (0.65) | ADORA2AADORA1AHCYADORA2BPI4KA | |
| SCHEMBL13952171 | 0.92 | ADORA2A (0.63) | ADORA2AADORA1AHCYADORA2BPI4KA | |
| SCHEMBL5965418 | 0.87 | ADORA2A (0.74) | ADORA2AADORA1AHCYADORA2BPI4KA | |
| SCHEMBL987631 | 0.87 | ADORA2A (0.74) | ADORA2AADORA1AHCYADORA2BPI4KA | |
| SCHEMBL7745013 | 0.85 | AHCY (0.76) | ADORA2AADORA1AHCYADORA2BPI4KA | |
| SCHEMBL12418038 | 0.83 | ADORA2A (0.63) | ADORA2AADORA1AHCYADORA2BPI4KA | |
| SCHEMBL8839648 | 0.83 | AHCY (0.68) | ADORA2AADORA1AHCYADORA2BPI4KA | |
| SCHEMBL11487766 | 0.83 | ADORA2A (0.71) | ADORA2AADORA1AHCYADORA2BPI4KA | |
| SCHEMBL984944 | 0.83 | ADORA2A (1.00) | ADORA2AADORA1AHCYADORA2BPI4KA | |
| SCHEMBL29459142 | 0.83 | ADORA2A (1.00) | ADORA2AADORA1AHCYADORA2BPI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115803033-A | Modified adenosine nucleosides for the treatment of viral infections | 詹皮特罗·亚切蒂尼 | 2023-03-14 | — | — | CN | disclosed |
| US-20090203636-A1 | Prevention and Treatment of Cancer and Other Diseases | ALT SOLUTIONS, INC. | 2009-08-13 | — | — | US | disclosed |
| US-20090203636-A1 | Prevention and Treatment of Cancer and Other Diseases | ALT SOLUTIONS, INC. | 2009-08-13 | — | — | US | disclosed |
| US-20090203636-A1 | Prevention and Treatment of Cancer and Other Diseases | ALT SOLUTIONS, INC. | 2009-08-13 | — | — | US | disclosed |
| EP-2001488-A2 | PREVENTION AND TREATMENT OF CANCER AND OTHER DISEASES | Alt Solutions, Inc. (US) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007106561-A2 | PREVENTION AND TREATMENT OF CANCER AND OTHER DISEASES | ALT SOLUTIONS, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007106561-A2 | PREVENTION AND TREATMENT OF CANCER AND OTHER DISEASES | ALT SOLUTIONS, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203636-A1 | Prevention and Treatment of Cancer and Other Diseases | TERT, POLRMT, RNASE1 | ADORA2A 1461/4885ADORA1 2194/4885AHCY 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.